제２형 당뇨병 환자에서 아포지단백 B와 대사증후군의 관계

Abstract

Background and aim : Increased low-density lipoprotein cholesterol (LDL-C) level and the presence of metabolic syndrome (MetS) are important risk factors for cardiovascular disease (CVD) in type 2 diabetes (T2DM). Recent studies demonstrated apolipoprotein B (apoB), a protein mainly located in LDL-C, was an independent predictor of the development of CVD especially in patients with T2DM. The aim of the study is to investigate the relationship between apoB and MetS in T2DM patients. Material and methods : We analyzed 912 patients with T2DM. Fasting blood samples were taken for HbA1c, hsCRP, total cholesterol, triglyceride (TG), HDL-C, LDL-C and apoB. MetS was defined by the modified National Choles-terol Education Program - Adult Treatment Panel (NCEP-ATP) III criteria. We performed a hierarchical regression analysis with apoB as the dependent variable. Age, sex, the number of components of MetS and LDL-C were en-tered at model 1, the use of lipid-lowering medications at model 2, and the in-dividual components of MetS were added at model 3. Results : Seventy percent of total subjects had the MetS. ApoB level was higher in subjects with MetS than those without MetS (104.5±53.3 vs 87.7±33.7 mg/dL; p<0.01) even after adjusting for LDL-C. ApoB and LDL-C were posi-tively correlated to NoMetS. The hierarchical regression analysis showed that the increasing number of MetS components was associated with higher level of apoB (β=0.120; p<0.001 and β=0.110; p<0.001, respectively) at model 1 and model 2. At model 3, TG (β=0.116; p<0.001) and systolic blood pressure (β=0.099; p<0.05) were significantly contributed to apoB.